Results 181 to 190 of about 312,617 (268)

Neurofilament Proteoforms in Amyotrophic Lateral Sclerosis Are Different in Cerebrospinal Fluid and Blood

Annals of Neurology, EarlyView.
We used targeted immunopurification‐mass spectrometry (IP‐MS) to characterize human neurofilament light chain (NfL) proteoforms across various compartments to assess their alterations in amyotrophic lateral sclerosis (ALS). NfL is truncated in cerebrospinal fluid (CSF) and blood in patients with sporadic ALS (sALS) and these proteoforms differ between ...
John B. Coulton, Yingxin He, Melissa M. Budelier, Nicolas Barthélemy, Margaret D. Ireland, Miwei Hu, Danielle Graham, Toby Ferguson, James D. Berry, Randall J. Bateman, Timothy M. Miller, Cindy V. Ly   +11 more
wiley   +1 more source

Defining the natural history of Alzheimer’s disease by longitudinal cerebrospinal fluid proteomics.

Tijms B, de Leeuw D, Trieu C, Jimenéz-Mausbach M, Fritz-Wallace K, Mjaavatten O, Bludjea E, Jutten R, Harten Av, Duits F, Braber Ad, Holstege H, Zwan M, Vijverberg E, Berven F, Teunissen C, Visser PJ.   +16 more
europepmc   +1 more source

Endovascular treatment of a sacral cerebrospinal fluid-venous Fistula using transvenous embolization: A case report. [PDF]

Interv Neuroradiol
Cagnazzo F, Ortiz Giraldo A, Lonjon N, Costalat V, Ducros A.   +4 more
europepmc   +1 more source

Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation

Annals of Neurology, EarlyView.
Objective Whether cognitive decline in patients with Parkinson's disease (PD) carrying GBA1 variants is accelerated after subthalamic deep brain stimulation (STN‐DBS) remains controversial. Clarifying long‐term cognitive outcomes is essential for informed decision making.
Moritz A. Loeffler, Philipp Klocke, Isabel Wurster, Stefanie Lerche, Idil Cebi, Thomas Gasser, Alireza Gharabaghi, Kathrin Brockmann, Daniel Weiss   +8 more
wiley   +1 more source

Alterations in cerebrospinal fluid levels of myelin- and oligodendrocyte-related proteins in sporadic Creutzfeldt-Jakob disease. [PDF]

Acta Neuropathol Commun
Maass F, Thomas C, Kurvits L, Hermann P, Schmitz M, Bähr M, Stadelmann C, Zechel S, Canaslan S, Zerr I.   +9 more
europepmc   +1 more source

Burst Pressure and Fatigue Durability of Commercially Available Duraplasty Sealants

International Forum of Allergy &Rhinology, EarlyView.
Katherine L. Lauritsen, Aishwarya V. Menon, Kaete A. Archer, Myah D. Webb, Jonathan Y. Ting, Jonathan J. Wilker, Julie C. Liu, Vijay R. Ramakrishnan   +7 more
wiley   +1 more source

Enhanced Sensitivity of a Modified Quaking‐Induced Conversion Diagnostic Test for the Broad Detection of Sporadic and Inherited Prion Diseases: A Retrospective Study

Annals of Neurology, EarlyView.
Objective Quaking‐induced conversion (QuIC) tests, which detect prion‐seeding activity in cerebrospinal fluid (CSF), have markedly advanced the antemortem diagnosis of prion diseases such as Creutzfeldt‐Jakob disease (CJD). These tests provide high diagnostic accuracy and enable timely differentiation from other rapidly progressive neurodegenerative ...
Jennifer Myskiw, Rebecca Fox, Dominic M.S. Kielich, Lise Lamoureux, Melanie Leonhardt, Olivia Nykvist, Jessy A. Slota, Kristen Avery, Clark Phillipson, Kathy Frost, Sharon Simon, Brian S. Appleby, Ben A. Bailey‐Elkin, Stephanie A. Booth   +13 more
wiley   +1 more source

When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ‐PET Centiloid 15, Mean Age of 66 Years

Annals of Neurology, EarlyView.
Objective Sporadic late‐onset Alzheimer's disease (AD) is characterized by a long pre‐clinical phase where amyloid‐beta (Aβ) and tau begin to accumulate in the brain. The primary objective was to determine the age at which AD starts by finding the average population age when both positron emission tomography (PET) Aβ (Aβ‐PET) and plasma Aβ42/40 become ...
Rodrigo Cánovas, Timothy Cox, Vincent Doré, Pierrick Bourgeat, Jurgen Fripp, Azadeh Feizpour, Rosita Shishegar, Christopher J. Fowler, Simon M. Laws, Tenielle Porter, Stephanie Rainey‐Smith, Leslie M. Shaw, Randall J. Bateman, Yan Li, Ovod Vitaliy, Michael W. Weiner, John C. Morris, Tammie L.S. Benzinger, Suzanne E. Schindler, Akinori Nakamura, Takeshi Iwatsubo, Takeshi Ikeuchi, Takashi Kato, Paul Maruff, Hamid R. Sohrabi, Christopher C. Rowe, Ralph N. Martins, Colin L. Masters, James D. Doecke, for the Alzheimer's Disease Neuroimaging Initiative   +29 more
wiley   +1 more source

Confined B‐Cell Reconstruction and High T‐Cell Clonality Define Clinical Response to Cladribine Treatment

Annals of Neurology, EarlyView.
Cladribine tablets are approved for relapsing multiple sclerosis, mediating their clinical effect by moderately depleting lymphocytes. In a prospective, monocentric study including 22 patients completing 2 annual cycles of cladribine, B‐ and T‐cell receptor repertoires and relapse activity were assessed at baseline and after 24 months. T‐cell clonality
Tilman Schneider‐Hohendorf, Maria Eveslage, Timo Wirth, Christian Wünsch, Eva M. Schumann, Jan D. Lünemann, Heinz Wiendl, Luisa Klotz, Nicholas Schwab   +8 more
wiley   +1 more source